California Jury Concludes Monsanto Weed Killer Caused Man’s Cancer

On Tuesday, a U.S. jury found that Roundup weed killer player a significant role to trigger cancer in a California man. The decision is the second strike against Bayer (former Monsanto), an herbicide manufacturer. Last year, in August, the company faced its first ever trial with the same scenario. At the time, the court concluded the same result as of the latest filing. The court awarded an amount of $289 million to DeWayne Johnson, who had cancer. California’s jury members agreed upon the fact that the product caused cancer to Johnson. They noted the company must have offered a label warning of the probable health hazard.

Thus it is the second jury to find that Bayer’s weed killer caused non-Hodgkin’s lymphoma. In this case, the sufferer is Edwin Hardeman, a 70-year-old man. The judge supervising the latest lawsuit divided the trial into two stages. Firstly, Edwin’s lawyers had to satisfy the jury members that the weed killer played a significant role to cause cancer. Secondly, the case will now proceed to the damages phase. Edwin claims that he used the product from decades in his 56-acre property present in Sonoma County. He was diagnosed with non-Hodgkin’s lymphoma in 2015.

In the next verdict, the jury will decide whether the company knew the risks, the product raised in users. It will also look into the matter whether those risks were knowingly hidden from users. On the other hand, Monsanto states researches have confirmed that glyphosate, an active ingredient in Roundup, is safe. According to the U.S. Environmental Protection Agency, glyphosate is not harmful to people if they use it as per label instructions. In a statement, Bayer disclosed disappointment with the court’s first decision. The company said they are sure the proof in the second phase will reveal that Monsanto’s did not perform any wrongdoing. As well as the company should not be responsible for Mr. Edwin’s cancer. Since it is a second case, but still 11,200 lawsuits are waiting for trial in the U.S.

Show More

Jason Amato

Jason was appointed to a three-year term at in September 2015. Later he was continued as the chief editor of the publication. In his role, Jason serves as the public's representative to He is responsible for bringing transparency to matters of journalism and journalism ethics. receives tens and thousands of inquiries annually and the Jason responds to significant queries, comments, and criticisms. Jason has a decade of experience taking an objective at the media industry and this experience has helped her is expertizing business and health sectors. So, when it's about business and health news, Jason is the go-to guy at

Leave a Reply

Your email address will not be published. Required fields are marked *